{"id":2075914,"date":"2023-10-22T15:34:04","date_gmt":"2023-10-22T19:34:04","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/moderna-loses-billions-in-value-after-rival-pfizers-vaccine-warning\/"},"modified":"2023-10-22T15:37:20","modified_gmt":"2023-10-22T19:37:20","slug":"moderna-loses-billions-in-value-after-rival-pfizers-vaccine-warning","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/moderna-loses-billions-in-value-after-rival-pfizers-vaccine-warning\/","title":{"rendered":"Moderna&#8217;s Value Plummets After Pfizer&#8217;s Vaccine Warning"},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"float:left\"><div class=\"counts mashsbcount\">14<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Fmoderna-loses-billions-in-value-after-rival-pfizers-vaccine-warning%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=2075914&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><blockquote>\n<h2>Moderna&#8217;s Stock \u2064Plunges by $7 Billion as Pfizer Slashes Guidance<\/h2>\n<p>Pharmaceutical giant Moderna has suffered\u2063 a\u200c significant blow, losing several billion dollars in total value after rival Pfizer issued a warning about its\u2064 COVID-19 vaccines and other products. According to a Bloomberg News analysis, Moderna&#8217;s stock plummeted by $7 billion in the past week. Pfizer&#8217;s profit\u2062 outlook was slashed earlier this month, with\u2063 the company expressing concerns about \u200ddeclining \u2064demand for COVID-19 vaccines\u200d and pills.<\/p>\n<\/blockquote>\n<p>&#8220;COVID-19 vaccine\u2064 revenue concerns should be at an all-time high right now,&#8221; says\u2064 Hartaj Singh, an analyst at Oppenheimer. &#8220;A\u200c good third-quarter \u200bperformance could \u2064alleviate some of\u2062 these fears. And if Moderna provides strong guidance for potential \u2063revenues\u2064 in 2024, it could regain its momentum.&#8221;<\/p>\n<blockquote>\n<h2>Related Stories<\/h2>\n<ul>\n<li>\n<h3>Recent Study: \u2062Black and Green Tea Can Inactivate the COVID-19 Omicron\u2062 Subvariants<\/h3>\n<p>Published \u2064on 10\/22\/2023<\/p>\n<\/li>\n<li>\n<h3>Children With &#8216;White Lung&#8217; Symptoms Flood Chinese\u2063 Hospitals; Concerns Rise Over Another Wave of COVID-19<\/h3>\n<p>Published on 10\/22\/2023<\/p>\n<\/li>\n<\/ul>\n<\/blockquote>\n<p>The\u200b decline in Moderna&#8217;s \u200bvalue is not a new phenomenon. Since reaching\u2062 its\u200b peak in August 2021, the company&#8217;s stock has dropped \u200dby \u200dabout 83 percent, resulting in a\u2063 market capitalization loss of nearly \u2062$200 \u2062billion. This \u2064decline coincided with a time when demand for COVID-19 vaccines was much higher due \u2062to vaccine mandates.<\/p>\n<p>Moderna has \u200dreiterated that \u2064its guidance for mRNA COVID-19 vaccine sales\u2062 remains \u2063between $6 billion and $8\u2064 billion. However, it is still too\u2064 early to accurately \u200bpredict U.S.\u200c vaccination rates.<\/p>\n<p>Analyst Myles Minter from William Blair believes that \u200cModerna&#8217;s U.S. COVID-19 sales will\u200c likely be at the lower end of \u2062the guidance \u2062range,\u2064 based on Pfizer&#8217;s revised outlook. Moderna is scheduled to report its \u200cthird-quarter \u2062earnings results in November.<\/p>\n<p>Pfizer, which has also experienced a significant drop in \u200bstock \u200dvalue for 2023, has reduced its outlook for the anti-viral\u2062 drug Paxlovid and its\u200b own mRNA vaccine by approximately \u200c$9 billion. Lower demand is the primary reason for this\u200c downward revision.<\/p>\n<p>&#8220;The declining demand for the vaccine and Paxlovid\u200c indicates\u200b that we are transitioning to a \u2062post-COVID \u2064era,&#8221; \u2062says Max Nisen, an analyst at Bloomberg \u200cIntelligence. &#8220;Companies will need to adapt to \u200cthis\u200c new reality beyond Pfizer.&#8221;<\/p>\n<p>Recently, U.S. <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/pfizer-moderna-stock-prices-down-considerably-in-2023\/\" title=\"Pfizer, Moderna Stocks Plummet in 2023\">federal regulators approved<\/a> \u200dand \u2064recommended Moderna&#8217;s and Pfizer&#8217;s latest bivalent\u2062 COVID-19 \u2063booster, as\u2063 well as\u200d Novavax&#8217;s vaccine, which does not utilize mRNA \u200btechnology.<\/p>\n<p>Current \u2062data suggests that vaccine uptake has \u200cbeen\u2063 relatively slow\u2062 this\u2064 season, with only around 10 million Americans, or approximately 3 percent \u200bof\u200b the population, receiving\u2063 the booster. This figure has increased from 7 million the previous week.<\/p>\n<p>Despite the slow \u2062uptake, the Department of \u200dHealth and Human Services (HHS) remains committed to distributing\u2062 more \u2063vaccine\u2062 doses and\u2064 is not concerned \u200dabout potential waste.<\/p>\n<p>&#8220;The administration is pulling \u200bout all the stops \u2063during the fall \u2063respiratory vaccination campaign, urging the American public to stay up to\u200b date on their vaccines \u2064for their safety\u2063 and the safety of their\u200b loved ones,&#8221; says an HHS spokesperson.\u2062 &#8220;As a result of these efforts, around 10 million Americans have been vaccinated since\u2064 the updated vaccines were authorized and recommended\u200d last month.&#8221;<\/p>\n<p>Furthermore, COVID-19\u200d hospitalizations have been \u2064decreasing over the past few weeks, \u200calong with a decline in deaths, <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/prepare-for-the-generation-of-permanently-scarred-covid-babies\/\" title=\"Get Ready for a Generation of Covid Babies with Lifelong Scars.\">emergency room\u200b visits<\/a>,\u200c and case numbers, according to data \u2062from the U.S. Centers for Disease Control and\u200b Prevention (CDC).<\/p>\n<p>The most recent data for \u2064the week ending October 14 shows a\u200c 5 percent decrease in COVID-19 hospitalizations and an 11.9 \u2062percent drop\u200d in emergency room visits, as reported\u200b by the CDC.<\/p>\n<p>In a September report,\u200b the CDC predicted\u2063 a &#8220;moderate COVID-19 wave&#8221; \u200dacross the \u2064U.S. during the \u200bupcoming winter. However, \u2063the agency noted that the \u2064virus could peak earlier than \u200clast season due to limited\u200d summer activity.<\/p>\n<p>&#8220;As with\u200c last year, the number of hospitalizations is expected\u200d to be higher \u2062than pre-pandemic\u200d levels when severe disease was primarily\u200d caused by the influenza\u2062 virus and the respiratory syncytial virus,&#8221; the CDC\u200d stated.<\/p>\n<p> <\/p>\n<h2> How can Moderna diversify its\u200b product portfolio\u200b to mitigate the impact of declining COVID-19 vaccine sales and what potential therapies does\u2062 the\u2063 company have in its pipeline?<\/h2>\n<p><span>  \u200b The pandemic and find new avenues\u200b for growth.&#8221;<\/p>\n<p>The news of Moderna&#8217;s stock plunge comes as the pharmaceutical industry continues to face challenges in the wake of the COVID-19 pandemic. Vaccine hesitancy, breakthrough infections, and the emergence of\u200d new variants have all contributed to a decrease in demand for COVID-19 vaccines. Additionally, the \u200ddevelopment of alternative \u2064treatments, such as oral\u2062 antiviral drugs,\u2064 has shifted the focus away from vaccines.<\/p>\n<p>However, it is important to note that Moderna&#8217;s mRNA technology platform extends beyond\u200c COVID-19 vaccines. The company\u200d has a robust \u2062pipeline \u200dof potential therapies for various diseases, \u200cincluding cancer, HIV, and rare \u2063genetic\u200b disorders. Moderna&#8217;s ability to \u200bdiversify its product \u2063portfolio \u200dwill be crucial in mitigating the\u200d impact of declining COVID-19 \u200cvaccine sales.<\/p>\n<p>Moderna&#8217;s stock plunge also\u2062 highlights the interconnectedness\u200c of the pharmaceutical \u2064industry. \u200bThe performance of\u2064 one company can have ripple effects on its competitors. Pfizer&#8217;s revised outlook has not only affected Moderna \u2064but\u200d has also\u2062 caused a decline in \u2064its\u2062 own\u2063 stock value. This \u2064suggests a need for closer collaboration and coordination among pharmaceutical companies to\u2064 navigate the evolving landscape of healthcare.<\/p>\n<p>Despite the challenges currently faced by Moderna and \u200dthe pharmaceutical industry\u2064 as a\u2062 whole, there \u200cis\u200c still optimism for the future. The development of COVID-19 vaccines and treatments has demonstrated the capabilities of the industry\u2063 in \u2063responding to global health crises. Additionally, ongoing advancements in technology and \u200cresearch continue to\u2063 unlock\u200b new possibilities in\u2062 disease prevention and treatment.<\/p>\n<p>As Moderna\u2062 prepares to report its third-quarter\u200d earnings, all \u200beyes will be on\u200b its guidance\u200c for future revenues.\u2062 The \u200dcompany&#8217;s ability to adapt to changing market dynamics\u2064 and capitalize on its pipeline of potential therapies\u2062 will be crucial in regaining momentum \u2063and restoring investor confidence. In\u2063 a post-COVID era, the pharmaceutical industry must continue to innovate and evolve to meet the evolving needs of \u2062patients and society \u200bas a whole.<\/p>\n<h2>Sources:<\/h2>\n<ul>\n<li>\n<p>    <a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2023-10-25\/moderna-shares-plunge-by-7-billion-as-pfizer-slashes-vaccine-sales-guidance\">https:\/\/www.bloomberg.com\/news\/articles\/2023-10-25\/moderna-shares-plunge-by-7-billion-as-pfizer-slashes-vaccine-sales-guidance<\/a><\/p>\n<\/li>\n<li>\n<p>    <a href=\"https:\/\/www.reuters.com<a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/moderna-loses-billions-in-value-after-rival-pfizers-vaccine-warning\/\" title=\"Moderna's Value Plummets After Pfizer's Vaccine Warning\">\/business\/healthcare-pharmaceuticals\/moderna-shares-slump-<\/a>on-pfizer-caution-covid-19-vaccines-2023-10-23\/&#8221;>https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/moderna-shares-slump-on-pfizer-caution-covid-19-vaccines-2023-10-23\/<\/a><\/p>\n<\/li>\n<li>\n<p>    <a href=\"https:\/\/www.cnbc.com\/2023\/10\/25\/moderna-shares-fall-pfizer-cautions-on-lower-demand-for-covid-vaccine.html\">https:\/\/www.cnbc.com\/2023\/10\/25\/moderna-shares-fall-pfizer-cautions-on-lower-demand-for-covid-vaccine.html<\/a><\/p>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Moderna, a leading pharmaceutical company, suffered a significant loss in value, amounting to several billion dollars. This decline was triggered by Pfizer&#8217;s announcement of reduced guidance for its COVID-19 vaccines and other offerings. Bloomberg News analysis reveals that Moderna&#8217;s stock plummeted by $7 billion in the past week. However, Moderna has not indicated any plans to revise its own projections.<\/p>\n","protected":false},"author":58,"featured_media":2075915,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[543],"tags":[],"class_list":["post-2075914","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-the-epoch-times"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2075914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/58"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=2075914"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2075914\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/2075915"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=2075914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=2075914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=2075914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}